Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Efficacy of Everolimus in Patients With HR+/HER2- High Risk Early Stage Breast Cancer

ESMO-Virtual-Plenary-2021-February-1000x250px

The ESMO Virtual Plenaries are freely available to all healthcare professionals working in Oncology.

Programme

Welcome and introduction of the faculty; Scientific background and context

Rebecca Dent, National Cancer Centre Singapore, Singapore

Efficacy of everolimus in patients with HR+/HER2- high risk early stage breast cancer 

Thomas Bachelot, Centre Leon Berard, Lyon, France

Perspectives

Peter Schmid, Cancer Research UK Barts Centre - Barts and The London School of Medicine and Dentistry, London, UK

Discussion and Q&A

Faculty and online audience (via chat feature)

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings